BPC-157 10mg/mL

Route: Subcutaneous or intramuscular injection as directed by the prescriber.

• For subcutaneous administration: inject into the subcutaneous fat layer of the abdomen, thigh, or upper arm; rotate injection sites with each dose.
• Use sterile technique: cleanse injection site with an alcohol swab and allow to dry before injecting.
• Use a new sterile syringe and needle for each injection; do not reuse or share needles.
• Inspect the solution before each use; do not use if it appears cloudy, discolored, or contains particles.
• The prescriber will specify the injection site and volume per dose.

There are no FDA-approved dosing guidelines for BPC-157. Prescriber-determined dosing is based on clinical context and published preclinical and emerging human safety data:

• Dosing protocols vary in the literature; the prescriber will specify dose, frequency (e.g., once or twice daily), and duration of treatment.
• Reported human pilot study dosing involved intravenous infusion; subcutaneous use is common in prescriber-directed protocols.
• Final dose, frequency, and administration route are determined exclusively by the prescriber.

The precise mechanism of action of BPC-157 in humans is not fully elucidated. Based on preclinical research:

• BPC-157: Modulates focal adhesion kinase (FAK) and paxillin signaling pathways involved in cell migration and tissue repair. Stimulates angiogenesis via upregulation of VEGF and other angiogenic factors. Activates the nitric oxide system to promote vasodilation and tissue perfusion. Exhibits anti-inflammatory activity by modulating prostaglandin synthesis and neutrophil function. Demonstrates cytoprotective effects on gastrointestinal mucosa and accelerates healing in tendon, ligament, muscle, and bone in preclinical models.

BPC-157 is used off-label in prescriber-directed compounding contexts based on its preclinical profile in tissue repair, musculoskeletal healing, and cytoprotection. Human clinical trial data are limited; one pilot safety study in humans (Lee & Burgess, 2025, PMID: 40131143) examined intravenous BPC-157 in human subjects. Prescribers are responsible for evaluating the risk-benefit ratio given the absence of FDA-approved indications and limited large-scale human trial data.

Prescriber monitoring considerations:

• No established laboratory monitoring protocol exists; clinical assessment of response and adverse effects should guide decisions.
• Patients should be counseled that this is an investigational use without FDA-approved clinical endpoints.
• Monitor injection sites for erythema, induration, or infection.

Contraindications:

• Known hypersensitivity to BPC-157 or any formulation excipient
• Active malignancy (theoretical concern given angiogenic and tissue-proliferative effects)

Warnings & Precautions:

• BPC-157 is not FDA-approved for any indication in humans; long-term safety data in humans are very limited.
• Sterile injectable preparations require proper aseptic technique to prevent injection site infection or systemic infection.
• The angiogenic properties of BPC-157 are a theoretical concern in patients with cancer or at high risk for tumor growth; avoid in patients with active or recent malignancy.
• Prescribers must clearly communicate the investigational and non-FDA-approved status of this treatment to patients and document informed consent.

Drug Interactions:

• No established drug interactions in humans; interactions should be assessed clinically on a case-by-case basis given limited human data.

Common Side Effects: Based on available data: injection site reactions (erythema, pain, bruising); no serious systemic adverse events were identified in the available human pilot study. Longer-term and larger-scale safety data are not available.

Store refrigerated at 2–8°C (36–46°F). Protect from light; store in amber vials or wrapped to prevent light exposure. Do not freeze. Bring to room temperature before injection. Use before the beyond-use date assigned by Genesis Compounding per USP sterile compounding standards. Discard any unused portion per prescriber and pharmacy instructions.

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a sequence found in human gastric juice. It has been studied extensively in animal models for wound healing, musculoskeletal tissue repair, gastrointestinal protection, and anti-inflammatory effects. Human clinical data are limited, and it is not FDA-approved for any indication.

Is BPC-157 FDA-approved?

No. BPC-157 is not FDA-approved for any indication. This preparation is a 503A compounded prescription product prepared by Genesis Compounding based on a prescriber's individualized patient order. Patients should discuss the investigational nature of this treatment with their prescriber and provide informed consent.

How do I inject this medication?

Use sterile technique: cleanse the injection site with an alcohol swab, allow to dry, then inject subcutaneously into the designated area (typically abdomen, thigh, or upper arm) as instructed by your prescriber. Rotate injection sites. Use a new sterile syringe and needle for each dose. Never share needles.

How should I store BPC-157 injectable?

Store refrigerated (2–8°C / 36–46°F), protected from light. Do not freeze. Inspect the solution before each use—do not use if cloudy or discolored. Use before the beyond-use date labeled by Genesis Compounding.

What results can I expect?

Clinical outcomes in humans are not well-established due to limited clinical trial data. Your prescriber has assessed the available preclinical and emerging human evidence to determine whether this therapy is appropriate for your situation. Do not adjust the dose or frequency without consulting your prescriber.